285 related articles for article (PubMed ID: 25505502)
21. Toxic tau: structural origins of tau aggregation in Alzheimer's disease.
Mamun AA; Uddin MS; Mathew B; Ashraf GM
Neural Regen Res; 2020 Aug; 15(8):1417-1420. PubMed ID: 31997800
[TBL] [Abstract][Full Text] [Related]
22. [Drug development for tauopathy and Alzheimer's disease].
Takashima A
Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Aug; 30(4):177-80. PubMed ID: 20857696
[TBL] [Abstract][Full Text] [Related]
23. Systemic and network functions of the microtubule-associated protein tau: Implications for tau-based therapies.
Bakota L; Ussif A; Jeserich G; Brandt R
Mol Cell Neurosci; 2017 Oct; 84():132-141. PubMed ID: 28318914
[TBL] [Abstract][Full Text] [Related]
24. Recent advances in cellular biosensor technology to investigate tau oligomerization.
Lo CH
Bioeng Transl Med; 2021 Sep; 6(3):e10231. PubMed ID: 34589603
[TBL] [Abstract][Full Text] [Related]
25. Pathological Changes of Tau Related to Alzheimer's Disease.
Chu D; Liu F
ACS Chem Neurosci; 2019 Feb; 10(2):931-944. PubMed ID: 30346708
[TBL] [Abstract][Full Text] [Related]
26. The potential for beta-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous Tau in inducible mouse models of tauopathy.
Mocanu MM; Nissen A; Eckermann K; Khlistunova I; Biernat J; Drexler D; Petrova O; Schönig K; Bujard H; Mandelkow E; Zhou L; Rune G; Mandelkow EM
J Neurosci; 2008 Jan; 28(3):737-48. PubMed ID: 18199773
[TBL] [Abstract][Full Text] [Related]
27. Tau phosphorylation in neuronal cell function and dysfunction.
Johnson GV; Stoothoff WH
J Cell Sci; 2004 Nov; 117(Pt 24):5721-9. PubMed ID: 15537830
[TBL] [Abstract][Full Text] [Related]
28. Tau protein phosphorylation as a therapeutic target in Alzheimer's disease.
Lau LF; Schachter JB; Seymour PA; Sanner MA
Curr Top Med Chem; 2002 Apr; 2(4):395-415. PubMed ID: 11966463
[TBL] [Abstract][Full Text] [Related]
29. Tau Acts in Concert With Kinase/Phosphatase Underlying Synaptic Dysfunction.
Fan X; Xia L; Zhou Z; Qiu Y; Zhao C; Yin X; Qian W
Front Aging Neurosci; 2022; 14():908881. PubMed ID: 35711910
[TBL] [Abstract][Full Text] [Related]
30. Neurofibrillary tangles and tau phosphorylation.
Brion JP; Anderton BH; Authelet M; Dayanandan R; Leroy K; Lovestone S; Octave JN; Pradier L; Touchet N; Tremp G
Biochem Soc Symp; 2001; (67):81-8. PubMed ID: 11447842
[TBL] [Abstract][Full Text] [Related]
31. Cellular factors modulating the mechanism of tau protein aggregation.
Fontaine SN; Sabbagh JJ; Baker J; Martinez-Licha CR; Darling A; Dickey CA
Cell Mol Life Sci; 2015 May; 72(10):1863-79. PubMed ID: 25666877
[TBL] [Abstract][Full Text] [Related]
32. Tau therapeutic strategies for the treatment of Alzheimer's disease.
Churcher I
Curr Top Med Chem; 2006; 6(6):579-95. PubMed ID: 16712493
[TBL] [Abstract][Full Text] [Related]
33. Nmnat1 protects neuronal function without altering phospho-tau pathology in a mouse model of tauopathy.
Musiek ES; Xiong DD; Patel T; Sasaki Y; Wang Y; Bauer AQ; Singh R; Finn SL; Culver JP; Milbrandt J; Holtzman DM
Ann Clin Transl Neurol; 2016 Jun; 3(6):434-42. PubMed ID: 27547771
[TBL] [Abstract][Full Text] [Related]
34. Characteristics of tau oligomers.
Ren Y; Sahara N
Front Neurol; 2013; 4():102. PubMed ID: 23882258
[TBL] [Abstract][Full Text] [Related]
35. First transgenic rat model developing progressive cortical neurofibrillary tangles.
Filipcik P; Zilka N; Bugos O; Kucerak J; Koson P; Novak P; Novak M
Neurobiol Aging; 2012 Jul; 33(7):1448-56. PubMed ID: 21196063
[TBL] [Abstract][Full Text] [Related]
36. Tauopathies: recent insights into old diseases.
Delacourte A
Folia Neuropathol; 2005; 43(4):244-57. PubMed ID: 16416389
[TBL] [Abstract][Full Text] [Related]
37. Neuron-selective toxicity of tau peptide in a cell culture model of neurodegenerative tauopathy: essential role for aggregation in neurotoxicity.
Zhao K; Ippolito G; Wang L; Price V; Kim MH; Cornwell G; Fulenchek S; Breen GA; Goux WJ; D'Mello SR
J Neurosci Res; 2010 Nov; 88(15):3399-413. PubMed ID: 20882568
[TBL] [Abstract][Full Text] [Related]
38. O-GlcNAc modification of tau directly inhibits its aggregation without perturbing the conformational properties of tau monomers.
Yuzwa SA; Cheung AH; Okon M; McIntosh LP; Vocadlo DJ
J Mol Biol; 2014 Apr; 426(8):1736-52. PubMed ID: 24444746
[TBL] [Abstract][Full Text] [Related]
39. Tau phosphorylation, molecular chaperones, and ubiquitin E3 ligase: clinical relevance in Alzheimer's disease.
Kumar P; Jha NK; Jha SK; Ramani K; Ambasta RK
J Alzheimers Dis; 2015; 43(2):341-61. PubMed ID: 25096626
[TBL] [Abstract][Full Text] [Related]
40. Tauopathy: A common mechanism for neurodegeneration and brain aging.
Saha P; Sen N
Mech Ageing Dev; 2019 Mar; 178():72-79. PubMed ID: 30668956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
